Intensity Therapeutics of Westport has received it first U.S. patent.

The company’s lead drug is INT230-6, a novel anti-cancer drug product able to disperse through tumors and diffuse into cancer cells. The product. which  was identified from Intensity’s DfuseRxSM platform technology, can completely clear large tumors in animal models.